Minutia

We are working towards a transplant of insulin producing cells combined with nanosensors for diabetes that is so safe and effective we would put it in our own bodies and the bodies of people we love. We believe our ability to create more robust and controlled insulin producing cell transplants that can be monitored in vivo over time will revolutionize the current clinical landscape for diabetes and cell replacement therapy

Diabetes,insulin,cell therapy,nanosensors,gold nanoparticles,and transplant

Minutia operates in the Biotechnology industry.

Minutia's revenue is 11m - 100m

Minutia has 11 - 50 employees.